| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine, Division of Endocrinology and Metabolism, University of Texas Health Science Center San Antonio, Texas 78284
Address all correspondence and requests for reprints to: Dr. J. Pfeilschifter, Department of Medicine/Endocrinology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, Texas 78284
Abstract
Transforming growth factor-β (TGFβ), a polypeptide that controls growth and differentiation in many cell types and has recently been found in abundant amounts in bone, was examined for its effects on cells with the osteoblast phenotype using the clonal osteoblastic osteosarcoma cell line ROS 17/2.8. TGFβ increased alkaline phosphatase (AP) activity and the rate of collagen synthesis per cell. Cell proliferation was inhibited, and the morphological appearance of the cells was markedly changed. All effects were observed at concentrations as low as 0.1 ng/ml TGFβ. Increases in AP activity were detectable after 24 h and increased progressively with time. TGFβ increased AP activity under serum-free conditions and during thymidine-induced inhibition of DNA synthesis. The increase in AP activity mediated by TGFβ could be completely inhibited with actinomycin D and cycloheximide. 1,25-Dihydroxyvitamin D3 at 10–7 M slightly increased AP activity in ROS 17/2.8 cells, but strongly inhibited AP activity when the cells were pretreated with TGFβ. The data suggest that TGFβ stimulates expression of the osteoblastic phenotype in ROS 17/2.8 cells and that TGFβ may be an important regulator of local bone remodeling. (Endocrinology 121: 212–218,1987)
Footnotes
* This work was supported by Grants CA-40035 and AM-28149 from the NIH.
Recipient of a fellowship from the Deutsche Forschungsgemeinschaft, Bonn-Bad Godesberg, West Germany.
Received October 6, 1986.
This article has been cited by other articles:
 |
|
 |
|
  M. Handfield, H.V. Baker, and R.J. Lamont Beyond Good and Evil in the Oral Cavity: Insights into Host-Microbe Relationships Derived from Transcriptional Profiling of Gingival Cells Journal of Dental Research, March 1, 2008; 87(3): 203 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terabe, C. Khanna, S. Bose, F. Melchionda, A. Mendoza, C. L. Mackall, L. J. Helman, and J. A. Berzofsky CD1d-Restricted Natural Killer T Cells Can Down-regulate Tumor Immunosurveillance Independent of Interleukin-4 Receptor-Signal Transducer and Activator of Transcription 6 or Transforming Growth Factor-{beta}. Cancer Res., April 1, 2006; 66(7): 3869 - 3875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsuyama, M. Iwadate, M. Kondo, M. Saitoh, A. Hanyu, K. Shimizu, H. Aburatani, H. K. Mishima, T. Imamura, K. Miyazono, et al. SB-431542 and Gleevec Inhibit Transforming Growth Factor-{beta}-Induced Proliferation of Human Osteosarcoma Cells Cancer Res., November 15, 2003; 63(22): 7791 - 7798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shirakawa, H. Shiba, K. Nakanishi, T. Ogawa, H. Okamoto, K. Nakashima, M. Noshiro, and Y. Kato Transforming Growth Factor-beta-1 Reduces Alkaline Phosphatase mRNA and Activity and Stimulates Cell Proliferation in Cultures of Human Pulp Cells Journal of Dental Research, September 1, 1994; 73(9): 1509 - 1514. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Critchlow, Y. Bland, and D. Ashhurst The effects of age on the response of rabbit periosteal osteoprogenitor cells to exogenous transforming growth factor-beta 2 J. Cell Sci., January 2, 1994; 107(2): 499 - 516. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Komm, C. Terpening, D. Benz, K. Graeme, A Gallegos, M Korc, G. Greene, B. O'Malley, and M. Haussler Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells Science, July 1, 1988; 241(4861): 81 - 84. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
